New prostate cancer treatment improves outcome:
This article was originally published in Clinica
Executive Summary
Combining radiotherapy with hormonal treatment could combat advanced forms of prostate cancer, according to a five-year European study of over 400 patients. Patients who received radiotherapy and 36 monthly injections of goserelin acetate (Zoladex), which inhibits the production of the sex hormone testosterone, had a survival rate of 78% compared with 62% for those treated with radiation alone, reported a team from the European Organisation for Research and Treatment of Cancer. Their findings were presented at the European Conference on Clinical Oncology in Vienna earlier this month.